Despite the anticipated launch of generics of blockbuster brands, an increase in HIV prevalence and continued uptake of premium single-tablet regimens (STRs) will drive continued market growth during 2015-24.
This report addresses the following questions:
- Which brands will drive further growth in the HIV market during 2015-24, and why? - How successful have Triumeq's and Tivicay's launches been and where are they currently positioned in the treatment algorithm? - What are physicians' views on the breaking up of fixed-dose combinations to prescribe cheaper separate generic components? - What percentage of diagnosed patients are currently under medical care and receiving antiretroviral therapy? - How will recent updates to US and EU treatment guidelines affect prescribing patterns in newly diagnosed patients?
- Primary Research Methodology - Disease Definition and Diagnosis - Patient Segmentation - Country Treatment Trees - Current Treatment Options - Prescribing Trends - Unmet Needs in HIV - Impact of Generics
- Sources and Methodology - Forecast - Epidemiologist Insight - Strengths and Limitations